Free Trial

Lyra Therapeutics (LYRA) Competitors

Lyra Therapeutics logo
$9.25 +0.22 (+2.44%)
Closing price 04:00 PM Eastern
Extended Trading
$9.19 -0.06 (-0.66%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LYRA vs. DXR, NEPH, SPAI, MODD, ECOR, QTI, POCI, PYPD, NMTC, and TMDIF

Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Daxor (DXR), Nephros (NEPH), Safe Pro Group (SPAI), Modular Medical (MODD), electroCore (ECOR), QT Imaging (QTI), Precision Optics (POCI), PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry.

Lyra Therapeutics vs. Its Competitors

Lyra Therapeutics (NASDAQ:LYRA) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Lyra Therapeutics had 1 more articles in the media than Daxor. MarketBeat recorded 1 mentions for Lyra Therapeutics and 0 mentions for Daxor. Lyra Therapeutics' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company Overall Sentiment
Lyra Therapeutics Neutral
Daxor Neutral

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Daxor has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,711.39%. Daxor's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lyra Therapeutics-6,711.39% -295.52% -66.95%
Daxor N/A N/A N/A

Lyra Therapeutics presently has a consensus target price of $100.00, suggesting a potential upside of 981.08%. Daxor has a consensus target price of $25.00, suggesting a potential upside of 167.38%. Given Lyra Therapeutics' higher possible upside, research analysts clearly believe Lyra Therapeutics is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lyra Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Daxor
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Daxor has lower revenue, but higher earnings than Lyra Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lyra Therapeutics$1.53M8.04-$93.43M-$60.50-0.15
DaxorN/AN/AN/AN/AN/A

Lyra Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500.

Summary

Lyra Therapeutics and Daxor tied by winning 5 of the 10 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LYRA vs. The Competition

MetricLyra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.30M$2.37B$5.47B$8.92B
Dividend YieldN/A1.78%5.24%4.04%
P/E Ratio-0.158.9227.0520.14
Price / Sales8.04501.68380.7693.83
Price / CashN/A21.7726.2128.59
Price / Book1.044.528.005.58
Net Income-$93.43M$31.26M$3.16B$248.40M
7 Day Performance3.93%6.11%3.84%6.13%
1 Month Performance-61.90%5.75%3.04%7.78%
1 Year Performance-31.28%1.24%34.26%20.95%

Lyra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LYRA
Lyra Therapeutics
1.6557 of 5 stars
$9.25
+2.4%
$100.00
+981.1%
-33.6%$12.30M$1.53M-0.1550Analyst Upgrade
DXR
Daxor
N/A$9.79
+7.0%
$25.00
+155.4%
+16.0%$47.38MN/A0.0037Gap Down
NEPH
Nephros
1.6285 of 5 stars
$4.09
+6.0%
$5.00
+22.2%
+96.2%$43.35M$14.16M58.4430Positive News
High Trading Volume
SPAI
Safe Pro Group
N/A$2.75
+3.0%
N/AN/A$41.72M$2.17M-3.4011Gap Down
MODD
Modular Medical
N/A$0.75
+9.7%
N/A-51.1%$40.42MN/A-1.4620Gap Down
ECOR
electroCore
2.315 of 5 stars
$5.28
-3.1%
$25.50
+383.0%
-4.7%$39.18M$25.18M-3.3850
QTI
QT Imaging
N/A$1.39
+17.8%
N/A+99.5%$37.72M$4.00M0.00N/ANews Coverage
Gap Up
POCI
Precision Optics
N/A$4.90
-0.4%
N/A-22.0%$37.58M$19.10M-5.5180
PYPD
PolyPid
2.1034 of 5 stars
$3.53
-1.1%
$11.80
+234.3%
-13.8%$35.97MN/A-0.8280
NMTC
NeuroOne Medical Technologies
2.2139 of 5 stars
$0.68
-0.3%
$1.45
+113.8%
-9.1%$33.79M$3.45M-3.0820
TMDIF
Titan Medical
N/A$0.29
flat
N/A+600.0%$32.62M$17.63M-0.2350Gap Down

Related Companies and Tools


This page (NASDAQ:LYRA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners